| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962806682P | 2019-02-15 | 2019-02-15 |
| Publication Number | Publication Date |
|---|---|
| CL2021002152A1true CL2021002152A1 (es) | 2022-04-18 |
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2021002152ACL2021002152A1 (es) | 2019-02-15 | 2021-08-13 | Métodos para tratar el dolor de la superficie ocular |
| Country | Link |
|---|---|
| US (4) | US20200261456A1 (es) |
| EP (1) | EP3923909A1 (es) |
| JP (2) | JP7571037B2 (es) |
| KR (1) | KR20210129677A (es) |
| CN (1) | CN113453686B (es) |
| AU (2) | AU2020222348B2 (es) |
| BR (1) | BR112021015998A2 (es) |
| CA (1) | CA3130038A1 (es) |
| CL (1) | CL2021002152A1 (es) |
| IL (1) | IL284629A (es) |
| JO (1) | JOP20210217A1 (es) |
| MX (1) | MX2021009702A (es) |
| PH (1) | PH12021551968A1 (es) |
| SG (1) | SG11202107260VA (es) |
| WO (1) | WO2020165838A1 (es) |
| ZA (1) | ZA202104593B (es) |
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6994061B2 (ja)* | 2019-02-15 | 2022-01-14 | ノバルティス アーゲー | ４－（７－ヒドロキシ－２－イソプロピル－４－オキソ－４ｈ－キナゾリン－３－イル）－ベンゾニトリルの製剤 |
| US20230286924A1 (en)* | 2020-08-06 | 2023-09-14 | Novartis Ag | Crystalline forms of 4-(7-hydroxy-2-isopropyl-4-oxo-4h-quinazolin-3-yl)-benzonitrile and formulations thereof |
| CN119184616A (zh)* | 2024-09-03 | 2024-12-27 | 中山大学附属第三医院粤东医院(梅州市梅县区人民医院) | 一种疼痛等级的测评方法及其评估系统 |
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1280874B (de) | 1963-10-09 | 1968-10-24 | Boehringer Sohn Ingelheim | 2-Methyl-3-(2-dimethylaminophenyl)-8-amino-3H-chinazolon-(4) |
| GB0412769D0 (en) | 2004-06-08 | 2004-07-07 | Novartis Ag | Organic compounds |
| US7893260B2 (en) | 2005-11-04 | 2011-02-22 | Hydra Biosciences, Inc. | Substituted quinazolin-4-one compounds for antagonizing TRPV3 function |
| GB0525068D0 (en) | 2005-12-08 | 2006-01-18 | Novartis Ag | Organic compounds |
| GB0525069D0 (en) | 2005-12-08 | 2006-01-18 | Novartis Ag | Organic compounds |
| EP1999116A2 (en) | 2005-12-22 | 2008-12-10 | Prolexys Pharmaceuticals, Inc. | 3-aryl-substituted quinazolones, and uses thereof |
| TW200738232A (en) | 2006-01-31 | 2007-10-16 | Alcon Mfg Ltd | Use of vanilloid receptor-1 antagonists for the prevention and treatment of glaucoma |
| WO2008140750A1 (en) | 2007-05-10 | 2008-11-20 | Hydra Biosciences Inc. | Compounds for modulating trpv3 function |
| WO2009010529A1 (en) | 2007-07-18 | 2009-01-22 | Novartis Ag | Synergistic combinations of vr-1 antagonists and cox-2 inhibitors |
| TW200927192A (en) | 2007-11-19 | 2009-07-01 | Alcon Res Ltd | Use of TRPV1 receptor antagonists for treating dry eye and ocular pain |
| WO2009081222A1 (en) | 2007-12-21 | 2009-07-02 | Glenmark Pharmaceuticals, S.A. | Substituted tricyclic pyridine or pyrimidine vanilloid receptor ligands |
| EP2240467B1 (en) | 2008-01-09 | 2013-03-20 | Evotec AG | Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same |
| WO2009090548A2 (en) | 2008-01-17 | 2009-07-23 | Glenmark Pharmaceuticals, S.A. | 3-azabicyclo [3.1.0] hexane derivatives as vanilloid receptor ligands |
| US8394779B2 (en) | 2008-06-04 | 2013-03-12 | Children's Medical Center Corporation | Methods of modulating angiogenesis via TRPV4 |
| WO2010023512A1 (en) | 2008-08-28 | 2010-03-04 | Matrix Laboratories Ltd. | Novel vanilloid receptor modulators, process for their preparation and pharmaceutical compositions containing them |
| US8349852B2 (en)* | 2009-01-13 | 2013-01-08 | Novartis Ag | Quinazolinone derivatives useful as vanilloid antagonists |
| EP2316420B1 (en) | 2009-10-22 | 2014-02-26 | Consorzio Universitario Unifarm | Topical ophthalmic composition to reduce pain |
| EP2377850A1 (en) | 2010-03-30 | 2011-10-19 | Pharmeste S.r.l. | TRPV1 vanilloid receptor antagonists with a bicyclic portion |
| EP2390327A1 (en) | 2010-05-27 | 2011-11-30 | Sylentis S.A. | siRNA and their use in methods and compositions for the treatment and/or prevention of eye conditions |
| EP2627178B1 (en) | 2010-10-11 | 2018-05-02 | Merck Sharp & Dohme Corp. | Quinazolinone-type compounds as crth2 antagonists |
| CN102875480A (zh) | 2012-04-23 | 2013-01-16 | 中国药科大学 | 喹唑啉酮类血管抑制剂、其制备方法及其医药用途 |
| GB201215857D0 (en) | 2012-09-05 | 2012-10-24 | Sylentis Sau | siRNA and their use in methods and compositions for the treatment and/or prevention of eye conditions |
| US9827225B2 (en) | 2016-01-25 | 2017-11-28 | Jenivision Inc. | Use of prostacyclin antagonists for treating ocular surface nociception |
| TW201825458A (zh) | 2016-09-20 | 2018-07-16 | 英商葛蘭素史克智慧財產（第二）有限公司 | Ｔｒｐｖ４拮抗劑 |
| JP7106528B2 (ja) | 2016-09-20 | 2022-07-26 | グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッド | Ｔｒｐｖ４拮抗薬 |
| JP2019532054A (ja) | 2016-09-20 | 2019-11-07 | グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ （Ｎｏ．２） Ｌｉｍｉｔｅｄ | Ｔｒｐｖ４拮抗薬 |
| EP4431497A1 (en) | 2019-02-15 | 2024-09-18 | Bausch + Lomb Ireland Limited | Crystalline forms of 4-(7-hydroxy-2-isopropyl-4-oxo-4h-quinazolin-3-yl)-benzonitrile and formulations thereof |
| JP6994061B2 (ja) | 2019-02-15 | 2022-01-14 | ノバルティス アーゲー | ４－（７－ヒドロキシ－２－イソプロピル－４－オキソ－４ｈ－キナゾリン－３－イル）－ベンゾニトリルの製剤 |
| Publication number | Publication date |
|---|---|
| TW202045179A (zh) | 2020-12-16 |
| US20220193078A1 (en) | 2022-06-23 |
| AU2020222348B2 (en) | 2023-03-16 |
| IL284629A (en) | 2021-08-31 |
| BR112021015998A2 (pt) | 2021-10-05 |
| PH12021551968A1 (en) | 2022-05-23 |
| WO2020165838A1 (en) | 2020-08-20 |
| US11234982B2 (en) | 2022-02-01 |
| EP3923909A1 (en) | 2021-12-22 |
| KR20210129677A (ko) | 2021-10-28 |
| US20240342174A1 (en) | 2024-10-17 |
| US20200261456A1 (en) | 2020-08-20 |
| AU2020222348A1 (en) | 2021-08-05 |
| JP2022520832A (ja) | 2022-04-01 |
| JP7571037B2 (ja) | 2024-10-22 |
| WO2020165838A9 (en) | 2021-03-18 |
| ZA202104593B (en) | 2025-03-26 |
| MX2021009702A (es) | 2021-09-14 |
| US20210275529A1 (en) | 2021-09-09 |
| CN113453686B (zh) | 2025-04-15 |
| CA3130038A1 (en) | 2020-08-20 |
| AU2023203716A1 (en) | 2023-07-06 |
| AU2023203716B2 (en) | 2025-03-20 |
| JOP20210217A1 (ar) | 2023-01-30 |
| SG11202107260VA (en) | 2021-08-30 |
| CN113453686A (zh) | 2021-09-28 |
| JP2025004186A (ja) | 2025-01-14 |
| Publication | Publication Date | Title |
|---|---|---|
| CO2021010689A2 (es) | Formulaciones de 4-(7-hidroxi-2-isopropil-4-oxo-4h-quinazolin-3-il)-benzonitrilo | |
| CL2021002152A1 (es) | Métodos para tratar el dolor de la superficie ocular | |
| MX2021010193A (es) | Azepino-indoles y otros heterociclos para el tratamiento de trastornos cerebrales. | |
| NI202100029A (es) | 2-amino-n-heteroaril-nicotinamidas como inhibidores de nav 1.8 | |
| ECSP20069418A (es) | Compuestos heterocíclicos como inmunomoduladores | |
| CU20200014A7 (es) | Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona | |
| ECSP21093541A (es) | Compuestos para el tratamiento de enfermedades y trastornos asociados con braf | |
| CL2016002812A1 (es) | Uso de ácido 3-2,3,5,6-tetrafluoro-3-trifluorometoxi-bifenil-4-ilcarbamoil-tiofeno-2-carboxílico para preparar un medicamento útil para tratar una enfermedad ocular que es uveítis, ojo seco o causada por un adenovirus composición formulación. | |
| CO2020005459A2 (es) | Compuestos bicíclicos en puente como moduladores del receptor farnesoide x | |
| EP3863658C0 (en) | OPHTHALMIC COMPOSITION FOR THE TREATMENT OF DRY EYE | |
| MX2020007947A (es) | Inhibidores de erbb/btk. | |
| ECSP21080096A (es) | Composiciones y métodos para el tratamiento de enfermedades mediadas por kit y pdgfra | |
| MX2021010870A (es) | Bloqueadores de canales ionicos cargados y metodos de uso. | |
| CL2020001183A1 (es) | Implantes de liberación sostenida para reducir la presión intraocular con duración prolongada del efecto. | |
| EA202092719A1 (ru) | Бензолсульфонамидные соединения и их применение в качестве терапевтических средств | |
| EA202090180A1 (ru) | Композиции nk1-антагониста и способы лечения депрессии | |
| EA202190576A1 (ru) | Полиморфные соединения и их применение | |
| MX2021002652A (es) | Uso de inhibidores de caseina-cinasa 1 para el tratamiento de enfermedades vasculares. | |
| CL2019002583A1 (es) | Inhibidores duales de magl y faah. | |
| DK3886858T3 (da) | Forbindelser til behandling af øjensygdomme forbundet med for megen vaskularisering | |
| CL2020000855A1 (es) | Anticuerpos monoclonales anti-trkb y métodos de uso. | |
| CO2022000214A2 (es) | Composiciones para el tratamiento de la pérdida del cabello | |
| EA202190590A1 (ru) | Соединения и способы лечения грибковых инфекций | |
| CL2023002236A1 (es) | Métodos para tratar la amiloidosis primaria | |
| EA202190523A1 (ru) | Замещенные индолы и способы их применения |